{"id":3153,"date":"2024-06-10T11:22:29","date_gmt":"2024-06-10T15:22:29","guid":{"rendered":"https:\/\/cytel.agencyukdev.com\/perspectives\/comparative-effectiveness-methods-and-techniques-for-better-decision-making\/"},"modified":"2024-08-21T11:17:29","modified_gmt":"2024-08-21T15:17:29","slug":"comparative-effectiveness-methods-and-techniques-for-better-decision-making","status":"publish","type":"perspectives","link":"https:\/\/cytel.agencyukdev.com\/fr\/perspectives\/comparative-effectiveness-methods-and-techniques-for-better-decision-making\/","title":{"rendered":"Comparative Effectiveness: Methods and Techniques for Better Decision-Making"},"content":{"rendered":"

Health technology assessment (HTA) submissions require cost effectiveness analyses based on comparative effectiveness studies of survival benefits vs. standard-of-care options in each specific geography. Ideally, these submissions are based on large, randomized control trials (RCTs), however, most new drugs approved in the last five years, specifically in oncology and rare diseases, are being approved based on small clinical trials, often un-controlled or single arm. Often, these trials do not have overall survival as the primary efficacy parameter.<\/p>\n

Thus, the dilemma: comparative evidence is still required for HTA submissions, but traditional investigative methods are no longer suitable to support value proposition. So where do we go from here?<\/p>\n

 <\/p>\n

There is a wide range of comparative effectiveness methods, and while some vendors tend to rely on the methods they’re most familiar with, they may not be fit for purpose. This issue is addressed in the first webinar of a four-part series on making better decisions using innovative comparative effectiveness methods, where Vice President, HEOR EU, Maria Rizzo and Vice President, HEOR Global, Bart Heeg discuss why you should use specific methods for specific cases. They also outline innovative methods that may be very helpful when data are insufficient.<\/p>\n

 <\/p>\n

The Maze of Methods and the Difficulty in Conducting an ITC Feasibility Assessment<\/strong><\/span><\/p>\n

When it comes to indirect treatment comparisons (ITCs) conducted to support HTA decision-making, explains Maria, there is a maze of ITC solutions available. The first critical step is to complete a feasibility assessment in order to navigate this maze.<\/p>\n

There are four main considerations when conducting a feasibility assessment:<\/p>\n